share_log

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

CRISPR Therapeutics | 144：擬議出售證券
SEC announcement ·  03/16 04:51
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 20,000 shares of common stock on 03/15/2024, with an aggregate market value of $1,449,628. The shares to be sold were acquired on the same date through a stock option exercise from the issuer, with payment made in cash. This transaction follows a series of sales over the past three months, where a total of 110,755 shares were sold for gross proceeds of $7,498,550.49.
CRISPR Therapeutics AG officer and director Samarth Kulkarni is set to sell 20,000 shares of common stock on 03/15/2024, with an aggregate market value of $1,449,628. The shares to be sold were acquired on the same date through a stock option exercise from the issuer, with payment made in cash. This transaction follows a series of sales over the past three months, where a total of 110,755 shares were sold for gross proceeds of $7,498,550.49.
CRISPR Therapeutics AG高管兼董事薩瑪斯·庫爾卡尼定於2024年3月15日出售2萬股普通股，總市值爲1,449,628美元。擬出售的股票於同日通過發行人的股票期權行使收購，並以現金支付。該交易是在過去三個月進行了一系列銷售之後進行的，共出售了110,755股股票，總收益爲7,498,550.49美元。
CRISPR Therapeutics AG高管兼董事薩瑪斯·庫爾卡尼定於2024年3月15日出售2萬股普通股，總市值爲1,449,628美元。擬出售的股票於同日通過發行人的股票期權行使收購，並以現金支付。該交易是在過去三個月進行了一系列銷售之後進行的，共出售了110,755股股票，總收益爲7,498,550.49美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。